

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313 on JANUARY 21, 2004.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE STATEMENT

Examining Group 1646

Patent Application

Docket No. G-029US05DIV

Serial No. 10/650,507

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Applicants : Bernard Bihain, Lydie Bougueleret, Frances Yen-Potin
Serial No. : 10/650,507
Filed : August 27, 2003
Conf. No. : 6971
For : LSR Receptor, Its Activity, Its Cloning, and Its Applications to the Diagnosis, Prevention and/or Treatment of Obesity and Related Risks or Complications

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §§1.97 and 1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:


U.S. Serial No. 09/269,939, filed April 6, 1999, now U.S. Patent No. 6,635,431.

The subject application, Serial No. 10/650,507, claims the benefit under 35 USC §120 of the filing date of patent application Serial No. 09/269,939. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/269,939 application, as well as any references cited during the prosecution thereof, be made of record in the 10/650,507 application.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/dkt

Attachment: Form PTO/SB/08



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,507
Filing Date	August 27, 2003
First Named Inventor	Bernard Bihain
Art Unit	1646
Examiner Name	Not Yet Known
Attorney Docket Number	G-029US05DIV

Sheet

1

of

6

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,635,373	06-03-1997	Wozney <i>et al.</i>	All
	U2	US-6,126,939	10-03-2000	Eisenbach-Schwartz <i>et al.</i>	All
	U3	US-5,270,170	12-14-1993	Schatz <i>et al.</i>	All
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1	WO 96/30400 A1	10-03-1996	Tanox Biosystems, Inc.	All	
	F2	WO 97/27286 A1	07-31-1997	Progenitor, Inc.	All	
	F3	WO 96/34981 A2	11-07-1996	Genset	All	
	F4	WO 96/39429 A2	12-12-1996	Whitehead Institute for Biomedical Research	All	
	F5	WO 98/01257 A2	01-15-1998	Van Den Bulcke	All	
	F6	WO 98/20165 A2	05-14-1998	Whitehead Institute for Biomedical Research	All	
	F7					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,507
				Filing Date	August 27, 2003
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	Not Yet Known
Sheet	2	of	6	Attorney Docket Number	G-029US05DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ALEXEEV and YOON "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," <i>Nature Biotech.</i> (1998), Volume 16, pages 1343-1346.	
	R2	AUSTIN, <i>et al.</i> "Hypertriglyceridemia as a Cardiovascular Risk Factor," <i>Am. J. Cardiol.</i> (1998), Volume 81, pages 7B-12B.	
	R3	BALDO, <i>et al.</i> "The Adipsin-Acylation Stimulating Protein System and Regulation of Intracellular Triglyceride Synthesis," <i>J. Clin. Invest.</i> (1993), Volume 92, pages 1543-1547.	
	R4	BARTLES, J.R., <i>et al.</i> "Biogenesis of the Rat Hepatocyte Plasma Membrane," <i>Methods Enzymol.</i> (1990), Volume 191, pages 825-841.	
	R5	BIHAIN, <i>et al.</i> "Characterization and purification of the lipolysis-stimulated receptor," INSERM U391, Universite de Rennes.	
	R6	BIHAIN, <i>et al.</i> "Free Fatty Acids Activate a High Affinity Saturable Pathway for Degradation of Low-Density Lipoproteins in Fibroblasts from a Subject Homozygous for Familial Hypercholesterolemia," <i>Biochemistry</i> (1992), Volume 31, number 19, pages 4628-4636.	
	R7	BRENDEL, V. <i>et al.</i> "Methods and algorithms for statistical analysis of protein sequences," <i>Proc. Natl. Acad. Sci. USA</i> (1992), Volume 89, pages 2002-2006.	
	R8	CHEN, W.J. <i>et al.</i> "NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor," <i>J. Biol. Chem.</i> (1990), Volume 265, pages 3116-3123.	
	R9	COLE-STRAUSS <i>et al.</i> "Correction of the Mutation Responsible for Sick Cell Anemia by an RNA-DNA Oligonucleotide," <i>Science</i> (1996), Volume 273, pages 1386-1389.	
	R10	DAVIS, C.G. <i>et al.</i> "The J.D. Mutation in Familial Hypercholesterolemia: Amino Acid Substitution in Cytoplasmic Domain Impedes Internalization of LDL Receptors," <i>Cell</i> (1986), Volume 45, pages 15-24.	
	R11	DIETRICH, J. <i>et al.</i> "CD3 γ Contains a Phosphoserine-Dependent Di-Leucine Motif Involved in Down-Regulation of the T Cell Receptor," <i>EMBO Journal</i> (1994), Volume 13, pages 2156-2166.	
	R12	EVERHART, J.E. "Weight Change and Obesity After Liver Transplantation: Incidence and Risk Factors," <i>Liver Transpl. Surg.</i> (1998), Volume 4, pages 285-296.	
	R13	FEEMAN, JR., W.E. "Hypertriglyceridemia and Atherosclerosis," <i>Annals of Internal Med.</i> (1998), Volume 128, number 1, pages 73-74.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,507
				Filing Date	August 27, 2003
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	Not Yet Known
Sheet	3	of	6	Attorney Docket Number	G-029US05DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	GHEBREHIWET, et al. "Isolation, cDNA Cloning, and Overexpression of a 33-kD Cell Surface Glycoprotein that Binds to the Globular "Heads" of C1q," <i>J. Exp. Med.</i> (1994), Volume 179, number 6, pages 1809-1821.	
	R15	GOLDSTEIN, J.L., et al. "Familial Hypercholesterolemia," in <i>The Metabolic and Molecular Bases of Inherited Disease</i> (Volume II, 7 th ed., Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, B. editors, 1995), pages 1981-2030; McGraw-Hill; New York, New York, USA.	
	R16	GOLDSTEIN, et al. "Hyperlipidemia in Coronary Heart Disease," <i>J. Clin. Invest.</i> (1973), Volume 52, pages 1533-1543.	
	R17	GURA, et al. "Obesity Sheds Its Secrets," <i>Science</i> (1997), Volume 275, pages 751-753.	
	R18	HAYWARD, et al. "The cDNA Sequence of Human Endothelial Cell Multimerin," <i>J. Biol. Chem.</i> (1995), Volume 270, pages 18246-18251.	
	R19	HENRION, et al. "Structure, Sequence and Chromosomal Location of the Gene for USF2 Transcription Factors in Mouse," <i>Genomics</i> (1995), Volume 25, pages 36-43.	
	R20	HERZ, J., et al. "Surface Location and High Affinity for Calcium of a 500-kd liver Membrane Protein Closely Related to the LDL-receptor Suggest a Physiological Role as Lipoprotein Receptor," <i>European Molecular Biology Laboratory</i> (1988), Volume 7, pages 4119-4127.	
	R21	HONORE, B., et al. "Cloning and Expression of a cDNA Covering the Complete Coding Region of the P32 subunit of Human pre-mRNA Splicing Factor SF2," <i>Gene</i> (1993), Volume 134, pages 283-287.	
	R22	HU, E., et al. "AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity," <i>J. Biol. Chem.</i> (1996), Volume 271, number 18, pages 10697-10703.	
	R23	HUETTINGER, M., et al. "Charecteristics of Chylomicron Remnant Uptake into Rat Liver," <i>Clin. Biochem.</i> (1988), Volume 21, pages 87-92.	
	R24	KARPE, F., et al. "Clearance of Lipoprotein Remnant Particles in Adipose Tissue and Muscle in Humans," <i>J. Lipid, Res.</i> (1997), Volume 38, pages 2335-2343.	
	R25	KARPE, F., et al. "Magnitude of Alimentary Lipemia is Related to Intima-media Thickness of the Common Carotid Artery in Middle-aged Men," <i>Elsevier Science Ireland</i> (1998), Volume 141, pages 307-314.	
	R26	KRAINER, A.R., et al. "Functional Expression of Cloned Human Splicing Factor SF2: Homology to RNA-Binding Proteins, U1 70K, and Drosophila Splicing Regulators," <i>Cell</i> (1991), Volume 66, pages 383-394.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B
(08-03)Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,507
				Filing Date	August 27, 2003
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	Not Yet Known
Sheet				Attorney Docket Number	G-029US05DIV
4				of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	LEE, M. G-S., et al. "Charecterization of a cDNA Encoding a Cysteine-Rich Cell Surface Protein Located in the Flagellar Pocket of the Protozoan <i>Trypanosoma brucei</i> ," <i>Molec. Cell. Biol.</i> (1990), Volume 10, pages 4506-4517.	
	R28	LETOURNEUR, F., et al. "A Novel Di-Leucine Motif and a Tyrosine-Based Motif Independently Mediate Lysosomal Targeting and Endocytosis of CD3 Chains," <i>Cell</i> (1992), Volume 69, pages 1143-1157.	
	R29	LEWIS, G.F., et al. "Postprandial Lipoprotein Metabolism in Normal and Obese Subjects: Comparison after the Vitamin A Fat-Loading Test," <i>J. of Clinic. Endo.</i> (1990), Volume 71, pages 1041-1050.	
	R30	LIN, et al. "Archaic Structure of the Gene Encoding Transcription Factor USF," <i>Journal of Biological Chemistry</i> (1994), Volume 269, number 19, pages 23894-28903.	
	R31	LIU, Q., et al. "Design of Polydactyl Zinc-finger Proteins for Unique Addressing within Complex Genomes," <i>Proc. Natl. Acad. Sci. USA</i> (1997), Volume 94, pages 5525-5530.	
	R32	MAEDA, et al. "cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (Adipose Most Abundant Gene Transcript 1)," <i>Biochem. And Biophys. Research Comm.</i> (1996), Volume 221, pages 286-289.	
	R33	MAHLEY, R.W., et al. "Type III Hyperlipoproteinemia (Dysbetalipoproteinemia): The Role of Apolipoprotein E in Normal and Abnormal Lipoprotein Metabolism," in <i>The Molecular Basis of Inherited Disease</i> (1995), pages 1953-1980; Scriver CR, Beaudet, A.L., Sly, W.S., Valle, D., editors; McGraw-Hill; New York.	
	R34	MANN, et al. "Mechanism of Activation and Functional Significance of the Lipolysis-Stimulated Receptor. Evidence for Role as Chylomiscron Remnant Receptor," <i>Biochemistry</i> (1995), Volume 34, number 33, pages 10421-10431.	
	R35	MASSIE, et al. "Inducible Overexpression of a Toxic Protein by an Andenovirus Vector with a Tetracycline-Regulatable Expression Cassette," <i>Journal of Virology</i> (1998), Volume 72, pages 2289-2296.	
	R36	MONTAGUE, et al. "Congenial Leptin Deficiency is Associated with Severe Early-onset Obesity in Humans," <i>Nature</i> (1997), Volume 387, pages 903-908.	
	R37	PARRA-LOPEZ, C.A., et al. "Presentation on Class II MHC Molecules of Endogenous Lysozyme Targeted to the Endocytic Pathway," <i>J. Immunol.</i> (1997), Volume 158, pages 2670-2679.	
	R38	PENGUE, G., et al. "Repression of Transcriptional Activity at a Distance by the Evolutionary Conserved KRAB Domain Present in a Subfamily of Zinc Finger Proteins," <i>Nucleic Acids Research</i> (1994), Volume 22, number 15, pages 2908-2914.	
	R39	RAJPUT-WILLIAMS,J., et al. "Variation of Apolipoprotein-B Gene is Associated with Obesity, High Blood Cholesterol Levels, and Increased Risk of Coronary Heart Disease," <i>The Lancet</i> (1988), pages 1442-1446.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,507
				Filing Date	August 27, 2003
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	Not Yet Known
Sheet	5	of	6	Attorney Docket Number	G-029US05DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	RUTHERFORD, S., et al. "Association of a Low Density Lipoprotein Receptor Micro-satellite Variant with Obesity," <i>Intl. J. of Obesity</i> (1997), Volume 21, pages 1032-1037.	
	R41	SCHAFFLER, et al. "Identification and Characterization of the Human Adipocyte apM-1 Promoter," <i>Biochem. and Biophys. Res. Comm.</i> (1998), Volume 1399, pages 187-189.	
	R42	SCHERER, et al. "A novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes," <i>J. Biol. Chem.</i> (1995), Volume 270, pages 26746-26749.	
	R43	SELLAR, et al. "Characterization and Organization of the Genes Encoding the A-, B-, and C-chains of human complement subcomponent C1q," <i>Biochemical Journal</i> (1991), Volume 274, pages 481-490.	
	R44	SHIMABUKURO, M., et al. "Direct Antidiabetic Effect of Leptin Through Triglyceride Depletion of Tissues," <i>Proc. Natl. Acad. Sci. USA</i> (1997), Volume 94, pages 4637-4641.	
	R45	SHIMANO, H., et al. "Overproduction of Cholesterol and Fatty Acids Causes Massive-Liver Enlargement in Transgenic Mice Expression Truncated SREBP-1a," <i>J. Clin. Invest.</i> (1996), Volume 98, pages 1575-1584.	
	R46	SHIN, J., et al. "Phosphorylation-dependent Down-modulation of CD4 Requires a Specific Structure within the Cytoplasmic Domain of CD4," <i>J. of Biol. Chem.</i> (1991), Volume 266, pages 10658-10665.	
	R47	SIMOS, G., et al. "The lamin B Receptor-associated Protein p34 Shares Sequence Homology and Antigenetic Determinants with the Splicing Factor 2-associated with Protein p32," <i>FEBS Letters</i> (1994), Volume 346, pages 225-228.	
	R48	STEINGRIMSSON, et al. "Murine Chromosomal Location of Five bHLH-Zip Transcription Factor Genes," <i>Genomics</i> (1995), Volume 28, pages 179-183.	
	R49	TROUSSARD, et al. "Inhibitory Effect on the Lipolysis-stimulated Receptor of the 39-kDa Receptor-associated Protein," <i>Journal of Biological Chemistry</i> (1995), Volume 270, number 29, pages 17068-17071.	
	R50	URADE, Y., et al. "Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain," <i>Proc. Natl. Sci. USA</i> (1991), Volume 88, pages 1069-1073.	
	R51	VAN DEN BERG, R.H., et al. "Intracellular Localization of the Human Receptor for the Globular Domains of C1q," <i>American Association of Immunologists</i> (1997), Volume 158, pages 3909-3916.	
	R52	VERHEY, K.J., et al. "A Leu-Leu Sequence is Essential for COOH-terminal Targeting Signal of GLUT4 Glucose Transporter in Fibroblasts," <i>J. Biol. Chem.</i> (1994), Volume 269, pages 2353-2356.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,507
				Filing Date	August 27, 2003
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	Not Yet Known
Sheet	6	of	6	Attorney Docket Number	G-029US05DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R53	WANG, et al. "Upstream Stimulatory Factor Binding to the E-box at -65 is required for Insulin Regulation of the Fatty Acid Synthase Promoter," <i>J. Biol. Chem.</i> (1997), Volume 272, pages 26367-26374.	
	R54	YEN, et al. "Identification of a Lipolysis-Stimulated Receptor That is Distinct from the LDL Receptor and the LDL Receptor Related Protein," <i>Biochemistry</i> (1994), Volume 33, number 5, pages 1172-1180.	
	R55	ZHANG, M., et al. "Tumor Necrosis Factor," in <i>The Cytokine Handbook</i> (3 rd ed., 1998), pages 517-548.	
	R56	ZHONG, G., et al. "Related Leucine-based Cytoplasmic Targeting Signals in Invariant Chain and Major Histocompatibility Complex Class II Molecules Control Endocytic Presentation of Distinct Determinants in a Single Protein," <i>J. Exp. Med.</i> (1997), Volume 185, pages 429-438.	
	R57	DATABASE EMBL, Entry MM49507, Accession No. U49507, May 20, 1996.	
	R58	DATABASE SPTREMBL_17, Accession No. Q61148, November 1, 1996.	
	R59	DATABASE EMBL, Q61127, Accession No. Q61148, November 1, 1996.	
	R60	DATABASE EMBL, Entry HSUSF2, Y07661, January 24, 1997.	
	R61	DATABASE EMBL, Entry HSAD684, AD000684, March 26, 1997.	
	R62	DATABASE EMBL, Entry HSAC2128, AC002128, May 28, 1997.	
	R63	DATABASE EMBL, Entry 000112, 0001127, July 1, 1997.	
	R64	DATABASE EMBL, Entry 000426, 000426, July 1, 1997.	
	R65	DATABASE SPTREMBL_17, Accession No. O00426, July 1, 1997.	
	R66	DATABASE SPTREMBL_17, Accession No. O00112, July 1, 1997.	
	R67	MANN, et al. Abstract: "ApoC111 Inhibits the Binding of Triglyceride-Rich Lipoproteins to the Lipolysis Stimulated Receptor," <i>Circulation</i> (1996), Volume 94, number 8, supp.I-698.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. END TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.